- Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with ...

REDWOOD CITY, California, Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...

(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests.

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Working from findings in the landmark TAILORx study, reseachers estimated that Oncotype DX-guided treatment could reduce the total first-year breast cancer care by nearly $50 million across the United ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. This is an ASCO Meeting Abstract from the 2019 ASCO ...

Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score ® Test REDWOOD CITY, Calif., United States, and MECHELEN, Belgium, ...